RECOMMENDED DOSING FOR OPDUALAG¹

• A recommended dose has not been established for pediatric patients who are 12 years or older and weigh less than 40 kg.
• Dose escalation or reduction is not recommended. Dosing delay or discontinuation may be required based on individual safety and tolerability.
• Please consult the OPDUALAG Product Monograph for complete dosage and administration instructions.

Q4W: every 4 weeks.

INSTRUCTIONS FOR PREPARATION^1,5

OPDIVO, as monotherapy or in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic melanoma who have not received prior systemic therapy for unresectable or metastatic melanoma.⁵
YERVOY is indicated for the treatment of unresectable or metastatic melanoma in adults who have not received prior systemic therapy for unresectable or metastatic melanoma, when used in combination with nivolumab.⁶

^* Comparative clinical significance unknown.